Upon ERBB3 ligand binding and subsequent hetero-dimerization with ERBB2, diverse signaling pathways may be activated, such as the PI3K/AKT pathway, which is heavily involved in promoting chemoresistance in many cancers [42–44]. The gene discussed is ERBB2; the disease is cancer.